Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:REGN NYSE:SNAP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.09-4.7%$6.92$4.25▼$9.85$2.37B0.431.72 million shs2.91 million shsREGNRegeneron Pharmaceuticals$564.63-0.9%$573.95$476.49▼$1,024.36$60.40B0.311.14 million shs1.49 million shsSNAPSnap$7.79-7.0%$7.69$6.90▼$13.28$14.16B0.71163.20 million shs78.32 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-4.77%-8.90%-14.88%-5.29%-23.25%REGNRegeneron Pharmaceuticals-0.92%-5.90%+1.58%-0.55%-44.22%SNAPSnap-7.26%-8.57%+10.26%-14.68%-27.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.09-4.7%$6.92$4.25▼$9.85$2.37B0.431.72 million shs2.91 million shsREGNRegeneron Pharmaceuticals$564.63-0.9%$573.95$476.49▼$1,024.36$60.40B0.311.14 million shs1.49 million shsSNAPSnap$7.79-7.0%$7.69$6.90▼$13.28$14.16B0.71163.20 million shs78.32 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-4.77%-8.90%-14.88%-5.29%-23.25%REGNRegeneron Pharmaceuticals-0.92%-5.90%+1.58%-0.55%-44.22%SNAPSnap-7.26%-8.57%+10.26%-14.68%-27.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 2.00Hold$9.0047.78% UpsideREGNRegeneron Pharmaceuticals 2.79Moderate Buy$817.4644.78% UpsideSNAPSnap 2.03Hold$34.65344.78% UpsideCurrent Analyst Ratings BreakdownLatest REGN, SNAP, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$761.00 ➝ $756.0010/8/2025BHCBausch Health CosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025REGNRegeneron PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025SNAPSnapWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025SNAPSnapWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$7.00 ➝ $8.009/29/2025SNAPSnapMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$9.009/29/2025SNAPSnapMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/27/2025BHCBausch Health CosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025REGNRegeneron PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025SNAPSnapWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/12/2025SNAPSnapGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$8.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.63B0.23$7.34 per share0.83($0.89) per share-6.84REGNRegeneron Pharmaceuticals$14.20B4.21$45.28 per share12.47$268.50 per share2.10SNAPSnap$5.36B2.46N/AN/A$1.47 per share5.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M$0.2623.421.31N/A0.99%-852.36%5.25%10/29/2025 (Estimated)REGNRegeneron Pharmaceuticals$4.41B$39.6814.2314.851.8231.37%15.06%11.77%10/28/2025 (Estimated)SNAPSnap-$697.86M-$0.32N/AN/AN/A-9.69%-23.32%-6.91%11/4/2025 (Estimated)Latest REGN, SNAP, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025SNAPSnap$0.06N/AN/AN/AN/AN/A10/29/2025Q3 2025BHCBausch Health Cos$1.12N/AN/AN/A$2.61 billionN/A10/28/2025Q3 2025REGNRegeneron Pharmaceuticals$9.73N/AN/AN/A$3.57 billionN/A8/5/2025Q2 2025SNAPSnap-$0.16-$0.16N/A-$0.16$1.34 billion$1.34 billion8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.43$12.89+$4.46$12.81$3.30 billion$3.68 billion7/30/2025Q2 2025BHCBausch Health Cos$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$3.520.62%N/A8.87%N/ASNAPSnapN/AN/AN/AN/AN/ALatest REGN, SNAP, and BHC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/1/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%8/18/20258/18/20259/3/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos141.901.310.98REGNRegeneron Pharmaceuticals0.094.603.72SNAPSnap1.733.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%REGNRegeneron Pharmaceuticals83.31%SNAPSnap47.52%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos19.97%REGNRegeneron Pharmaceuticals7.02%SNAPSnap22.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.81 million296.76 millionOptionableREGNRegeneron Pharmaceuticals15,106105.99 million98.55 millionOptionableSNAPSnap4,9111.69 billion1.31 billionOptionableREGN, SNAP, and BHC HeadlinesRecent News About These CompaniesSnap Inc. Stock (SNAP) Opinions on Ad Revenue Challenges and Legal PressuresOctober 11 at 10:11 AM | quiverquant.comQSnap Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Snap Inc. - SNAPOctober 10 at 11:48 PM | prnewswire.comHere's Why Snap (SNAP) Fell More Than Broader MarketOctober 10 at 7:01 PM | zacks.comSnap Inc. (SNAP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 10 at 4:20 PM | prnewswire.comSNAP INC REMINDER: Bragar Eagel & Squire, P.C. Urges Snap, Inc. Investors to Contact the Firm Before the October 20th DeadlineOctober 10 at 2:27 PM | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Snap, Inc. InvestorsOctober 10 at 12:02 PM | globenewswire.comAnalyst Highlights Potential Catalyst for Snap (SNAP) StockOctober 10 at 10:10 AM | insidermonkey.comSnap Inc. (SNAP) Faces Class Action Over Ad Platform, Investors Allege Misleading Statements -- Hagens BermanOctober 10 at 9:11 AM | prnewswire.comLost Money on Snap Inc.(SNAP)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyOctober 10 at 9:00 AM | prnewswire.comEuropean Commission reviews child safety on Snapchat, YouTube, app storesOctober 10 at 7:01 AM | reuters.comEU questions Apple, Google, Snapchat, YouTube over risks to childrenOctober 10 at 4:50 AM | techxplore.comTSNAP DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Snap Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SNAPOctober 9 at 4:34 PM | globenewswire.comShareholders of Snap Inc. Should Contact Levi & Korsinsky Before October 20, 2025 to Discuss Your Rights – SNAPOctober 9 at 4:24 PM | globenewswire.comSnap Inc. Announces Date of Third Quarter 2025 Results Conference CallOctober 9 at 4:10 PM | businesswire.comSnap Inc. (SNAP) Sued: Lawsuit Alleges Ad Platform ‘Execution Error' Concealed From Investors, According to Hagens BermanOctober 9 at 1:06 PM | globenewswire.comSNAP INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Snap Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitOctober 9 at 12:00 PM | globenewswire.comThe Gross Law Firm Reminds Snap Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 20, 2025 - SNAPOctober 9 at 8:45 AM | prnewswire.comSnap Shareholder Alert: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Snap Inc. - SNAPOctober 8 at 9:52 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Snap, Inc. of Class Action Lawsuit and Upcoming Deadlines - SNAPOctober 8 at 4:30 PM | prnewswire.comSnap Inc. Deadline: SNAP Investors with Losses in Excess of $100K Have Opportunity to Lead Snap Inc. Securities Fraud LawsuitOctober 8 at 3:03 PM | prnewswire.comSnap Inc. (NYSE:SNAP) Short Interest UpdateOctober 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Bargain Alert: DraftKings Is the Most Oversold It’s Ever BeenBy Sam Quirke | October 10, 2025REGN, SNAP, and BHC Company DescriptionsBausch Health Cos NYSE:BHC$6.09 -0.30 (-4.69%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$6.06 -0.03 (-0.49%) As of 10/10/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Regeneron Pharmaceuticals NASDAQ:REGN$564.63 -5.27 (-0.92%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$561.52 -3.11 (-0.55%) As of 10/10/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Snap NYSE:SNAP$7.79 -0.59 (-7.04%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$7.70 -0.09 (-1.16%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Snap Inc. operates as a technology company in North America, Europe, and internationally. The company offers Snapchat, a visual messaging application with various tabs, such as camera, visual messaging, snap map, stories, and spotlight that enable people to communicate visually through short videos and images. It also provides Spectacles, an eyewear product that connects with Snapchat and captures photos and video from a human perspective; and advertising products, including AR ads and Snap ads comprises a single image or video ads, collection ads, dynamic ads, story ads, and commercials. The company was formerly known as Snapchat, Inc. and changed its name to Snap Inc. in September 2016. Snap Inc. was founded in 2010 and is headquartered in Santa Monica, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
